# US 2004/0072753 A1 · Peptides for use in the treatment of alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072753 A1
- Document ID: US20040072753A1
- Status: Published application
- Kind: A1
- Application number: 10/415,383
- Filed: 2003-09-11
- Published: 2004-04-15
- Earliest claimed: 2000-11-01
- Inventors: Nathaniel Gavin Nicolas Milton
- Web page: https://patentgrep.com/patent/US20040072753A1

## CPC

- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Anti-sense peptides that correspond to Amyloid-β protein residues 1-43 are identified, and are used to identify protein binding sites on enzymes that interact with Amyloid-β. The anti-sense peptides can be used as, or to identify, therapeutic agents that prevent Amyloid-β cytotoxicity, and may be useful in the treatment of Alzheimer's disease. The anti-sense peptides show sequence similarity to the protein kinase cdc2, and it has now been found that the cytotoxic form of Aβ is phosphorylated.

## Claims

### Claim 1

A peptide comprising the anti-sense sequence of Aβ 1-43 (SEQ ID NO. 2), or a fragment thereof capable of binding to the Aβ protein within the Aβ 1-43 region, or a homologue of the peptide or the fragment having the same hydropathic profile or at least 60% sequence identity.

### Claim 2 (depends on 1)

A peptide according to claim 1, wherein the fragment comprises the anti-sense sequence of Aβ17-24 or Aβ31-35.

### Claim 3 (depends on 1, 2)

A peptide according to claim 1 or claim 2, which consists of the anti-sense sequence of Aβ 3-30, Aβ 17-35, Aβ 12-24, Aβ 12-28, Aβ 14-35 or Aβ 25-35, or a homologue thereof with at least 60% sequence identity.

### Claim 4

A peptide according to any preceding claim, comprising any of the sequences identified herein as SEQ ID NOS. 2, 6, 7, 8, 9 or 10 or a fragment thereof capable of binding to the Aβ protein within the Aβ1-43 region.

### Claim 5

A peptide according to any preceding claim, having a therapeutic or diagnostic agent bound thereto.

### Claim 6 (depends on 5)

A peptide according to claim 5, wherein the diagnostic agent is a detectable label.

### Claim 7 (depends on 5)

A peptide according to claim 5, wherein the therapeutic agent is an inhibitor of a protein kinase.

### Claim 8

A peptide according to any preceding claim for use in therapy.

### Claim 9

A phosphorylated Aβ protein, or a fragment thereof, for use in therapy.

### Claim 10 (depends on 9)

A protein according to claim 9, comprising a phosphorylated serine 26 residue.

### Claim 11 (depends on 1, 2, 3, 4)

An isolated recombinant vector comprising a polynucleotide that encodes a peptide according to any of claims 1 to 4.

### Claim 12 (depends on 1, 2, 3, 4)

An antibody, raised against a peptide according to any of claims 1 to 4.

### Claim 13 (depends on 9, 10)

An antibody, raised against a protein according to claim 9 or claim 10, the antibody having no or reduced affinity for the non-phosphorylated form of the protein.

### Claim 14

An antibody raised against a peptide comprising any of the sequences defined herein as SEQ ID NOS. 13 to 21.

### Claim 15 (depends on 14)

An antibody according to claim 14, raised against a peptide comprising any of the sequences defined herein as SEQ ID NOS. 13 to 17.

### Claim 16

An antibody raised against a peptide comprising any of the sequences defined herein as SEQ ID NOS. 13 to 16.

### Claim 17 (depends on 1, 2, 3, 4)

Use of a peptide according to any of claims 1 to 4, in the manufacture of a medicament, for therapy of a condition mediated by phosphorylation of Aβ.

### Claim 18

Use of a peptide comprising the amino acid sequence Aβ 1-43, or a fragment thereof capable of binding to cyclin-dependent kinase, in the manufacture of a medicament for therapy of a condition mediated by phosphorylation of Aβ.

### Claim 19 (depends on 1, 2, 3, 4)

Use of a peptide according to any of claims 1 to 4, in the manufacture of a medicament for therapy of a condition mediated by the binding of endogenous Aβ to catalase.

### Claim 20 (depends on 17, 18, 19)

Use according to any of claims 17 to 19, wherein the condition is Alzheimer's disease.

### Claim 21

Use of a protein kinase inhibitor in the manufacture of a medicament for the treatment of Alzheimer's disease.

### Claim 22 (depends on 21)

Use according to claim 21, wherein the inhibitor selectively binds to Aβ protein.

### Claim 23 (depends on 21, 22)

Use according to claim 21 or claim 22, wherein the kinase is p34-cdc2.

### Claim 24

A method for determining whether a patient is at risk from Alzheimer's disease, comprising analysing a sample from the patient that contains Aβ to determine whether Aβ is phosphorylated, where the detection of phosphorylation indicates a risk of Alzheimer's disease.

### Claim 25 (depends on 24)

A method according to claim 24, wherein phosphorylation is to be detected within the Aβ 1-43 region.

### Claim 26 (depends on 24, 25)

A method according to claim 24 or claim 25, wherein the phosphorylation to be detected is the phosphorylation of a serine amino acid residue.

### Claim 27 (depends on 24, 25, 26)

A method according to any of claims 24 to 26, wherein the sample is treated with an antibody that has affinity for Aβ 1 phosphorylated within the Aβ 1-43 region, and has no or reduced affinity for non-phosphorylated Aβ.

### Claim 28

An assay for the identification of an agent that inhibits the interaction of Aβ protein with other proteins, comprising contacting Aβ protein or a fragment thereof, with a target agent and a peptide that binds to Aβ (or the fragment), and determining whether the agent inhibits the peptide from binding to Aβ, compared to a control assay carried out in the absence of the peptide.

### Claim 29 (depends on 28)

An assay according to claim 28, wherein Aβ comprises at least Aβ 1-43.

### Claim 30 (depends on 1, 2, 3, 4, 28, 29)

An assay according to claim 28 or claim 29, wherein the peptide is that according to any of claims 1 to 4, a protein kinase enzyme, or cyclin, or a fragment thereof.

### Claim 31 (depends on 30)

An assay according to claim 30, wherein the protein kinase is cdc2.

### Claim 32 (depends on 28, 29)

An assay according to claim 28 or claim 29, wherein the peptide is catalase or ERAB, or a fragment thereof.

### Claim 33 (depends on 32)

An assay according to claim 32, wherein the peptide is less than 40 amino acids in length and comprises any of the sequences defined herein as SEQ ID NOS. 18 to 21.

### Claim 34 (depends on 18)

An assay for the identification of an agent that binds to Aβ within the region Aβ 1-43, comprising contacting a target agent with a peptide, as defined in claim 18, and determining whether the agent binds to the peptide.

### Claim 35 (depends on 34)

An assay according to claim 34, wherein the peptide is phosphorylated.

### Claim 36 (depends on 1, 2, 3, 4)

A vaccine composition, comprising a peptide according to any of claims 1 to 4, and a pharmaceutically acceptable diluent or adjuvant.

### Claim 37

A vaccine composition, comprising a phosphorylated Aβ protein, or a fragment thereof, and a pharmaceutically acceptable diluent or adjuvant.

### Claim 38 (depends on 36, 37)

A vaccine according to claim 36 or claim 37, comprising a Aβ peptide phosphorylated on one or more of residues 8, 10, 26 and 43, and a pharmaceutically acceptable diluent.

### Claim 39

A vaccine composition, comprising a peptide comprising any of the sequences defined herein as SEQ ID NO. 13 to SEQ ID NO. 17.

### Claim 40

A compound that blocks the activity of phosphorylated Aβ protein.
